Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study

Objective To examine the relation between plasma HIV-1 RNA concentrations in the community and HIV incidence among injecting drug users. Design Prospective cohort study. Setting Inner city community in Vancouver, Canada. Participants Injecting drug users, with and without HIV, followed up every six months between 1 May 1996 and 30 June 2007. Main outcome measures Estimated community plasma HIV-1 RNA in the six months before each HIV negative participant’s follow-up visit. Associated HIV incidence. Results Among 622 injecting drug users with HIV, 12 435 measurements of plasma HIV-1 RNA were obtained. Among 1429 injecting drug users without HIV, there were 155 HIV seroconversions, resulting in an incidence density of 2.49 (95% confidence interval 2.09 to 2.88) per 100 person years. In a Cox model that adjusted for unsafe sexual behaviours and sharing used syringes, the estimated community plasma HIV-1 RNA concentration remained independently associated with the time to HIV seroconversion (hazard ratio 3.32 (1.82 to 6.08, P<0.001), per log10 increase). When the follow-up period was limited to observations after 1 January 1988 (when the median plasma HIV RNA concentration was <20 000 copies/ml), the median viral load was no longer statistically associated with HIV incidence (1.70 (0.79 to 3.67, P=0.175), per log10 increase). Conclusions A longitudinal measure of community plasma HIV-1 RNA concentration was correlated with the community HIV incidence rate and predicted HIV incidence independent of unsafe sexual behaviours and sharing used syringes. If these findings are confirmed, they could help to inform both HIV prevention and treatment interventions.

[1]  R. Steinbrook The AIDS epidemic--a progress report from Mexico City. , 2008, The New England journal of medicine.

[2]  Jon Cohen Microbicide Fails to Protect Against HIV , 2008, Science.

[3]  S. Blower,et al.  Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1 , 2007, Annals of Internal Medicine.

[4]  J. Montaner,et al.  Frequent needle exchange use and HIV incidence in Vancouver, Canada. , 2007, The American journal of medicine.

[5]  R. Ashcroft,et al.  Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). , 2006, Addiction.

[6]  Evan Wood,et al.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic , 2006, The Lancet.

[7]  P. Harrigan,et al.  Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μl , 2006, AIDS.

[8]  J. Montaner,et al.  Safer injection facility use and syringe sharing in injection drug users , 2005, The Lancet.

[9]  P. Harrigan,et al.  When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. , 2005, The Lancet. Infectious diseases.

[10]  R. Hogg,et al.  Staging for antiretroviral therapy among HIV-infected drug users. , 2004, JAMA.

[11]  S. Twu,et al.  Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. , 2004, The Journal of infectious diseases.

[12]  L. Gardner,et al.  Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users , 2004, AIDS care.

[13]  D. Collet Modelling Survival Data in Medical Research , 2004 .

[14]  H. Gershengorn,et al.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.

[15]  Elliot Marseille,et al.  HIV prevention before HAART in sub-Saharan Africa , 2002, The Lancet.

[16]  M. Schechter,et al.  Impact of HIV infection on mortality in a cohort of injection drug users. , 2001 .

[17]  V. Soriano,et al.  Drug resistance in patients experiencing early virological failure under a triple combination including indinavir , 2001, AIDS.

[18]  E. Rosenberg,et al.  Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Holmes,et al.  Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men , 2000, AIDS.

[20]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[21]  A. Caliendo,et al.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.

[22]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[23]  E. Masliah,et al.  Changes in pathological findings at autopsy in AIDS cases for the last 15 years , 2000, AIDS.

[24]  C. Ferri,et al.  Epidemiological methods for research with drug misusers: review of methods for studying prevalence and morbidity. , 1999, Revista de saude publica.

[25]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[26]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[27]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[28]  P. Vernazza,et al.  Effect of antiviral treatment on the shedding of HIV‐1 in semen , 1997, AIDS.

[29]  Julio S. G. Montaner,et al.  Needle exchange is not enough: lessons from the Vancouver injecting drug use study , 1997, AIDS.

[30]  C. Lopes,et al.  The lack of selection bias in a snowball sampled case-control study on drug abuse. , 1996, International journal of epidemiology.

[31]  A. MacDonald Modelling Survival Data in Medical Research. By D. Collett (Chapman & Hall, 1994) £19.99 , 1995, British Actuarial Journal.

[32]  HIV vaccine failure prompts Merck to halt trial , 2007, Nature.

[33]  R. Williamson,et al.  Safer injection facility use and syringe sharing in injection drug users , 2022 .